HOME >> BIOLOGY >> NEWS
Mouse model advances understanding of synovial sarcoma

A mouse model for synovial sarcoma has enabled scientists to make tremendous progress toward understanding the origin and pathogenesis of this highly aggressive soft-tissue malignancy. The research, published in the April issue of the journal Cancer Cell, published by Cell Press, provides new information about the timing and environment required for initiation and progression of synovial sarcoma. The mouse model is also likely to serve as an invaluable resource for development of successful therapeutic strategies for this often lethal cancer.

Synovial sarcoma is associated with expression of a chimeric fusion protein called SYT-SSX. Dr. Mario R. Capecchi, from the Howard Hughes Medical Institute and the Department of Human Genetics at the University of Utah School of Medicine, and colleagues developed a mouse model that expresses human SYT-SSX in chosen target cells. Using this approach, the researchers discovered that, although it is named for its common proximity to limb joints, this tumor appears to arise from skeletal muscle precursor cells called myoblasts. Remarkably, expression of SYT-SSX in myoblasts was sufficient to induce synovial sarcoma with an astonishing 100% penetrance.

Use of a sophisticated conditional genetic technique allowed the researchers to control the timing of fusion protein expression so as to examine what happens when the protein is expressed at different stages of muscle development. Earlier expression of SYT-SSX disrupted normal development and was associated with embryonic lethality, while expression in more differentiated muscle cells induced significant muscle cell damage and death in the absence of tumor formation.

Further studies demonstrated that this mouse model of synovial sarcoma faithfully recapitulates human synovial sarcoma on multiple levels. As in the human cancer, tumors in the mice arise most commonly in close proximity to joints. The researchers speculate that the cartilage associa
'"/>

Contact: Erin Doonan
edoonan@cell.com
617-397-2802
Cell Press
9-Apr-2007


Page: 1 2

Related biology news :

1. Mouse FH knockout resembles human renal cell cancer
2. Mouse stem cell line advance suggests potential for IVF-incompetent eggs
3. Mouse model underestimates the critical role of Tyk2 in human immune system
4. Mouse DNA to aid biomedical research
5. Mouse strain with gene stutter will help leukemia research
6. Knockout Mouse Project
7. NIH launches Knockout Mouse Project
8. Mouse mimics chronic leukemia, will aid drug development
9. Mouse, frog and bird put Snail and Slug to different uses
10. Mouse study reveals human X-SCID gene therapy poses substantial cancer risk
11. Mouse to man: The story of chromosomes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/11/2018)... ... October 09, 2018 , ... ... and supports high-growth, high-impact life science and biotechnology companies, announced today that ... disease foundations to discuss their investment philosophies, explain their fund and deal ...
(Date:10/11/2018)... ... 11, 2018 , ... ODSC Europe 2018 - one of Open Data ... the event from September 19-22. , As Europe’s largest applied data science conference, ... and 4 days. Attendees were given key insights and hands-on training in ...
(Date:10/5/2018)... , ... October 05, 2018 , ... ... America, Inc. (AHN), is announcing a 10% price increase across all markets in ... amino acids — the building blocks of protein — for the parenteral nutrition, ...
Breaking Biology News(10 mins):
(Date:9/29/2018)... ... September 29, 2018 , ... ... and early-stage companies to access the power of influence analytics and data-driven engagement ... to a broader market that didn’t necessarily have access to the same financial ...
(Date:9/27/2018)... ... September 26, 2018 , ... Medable was named DPharm ... build the first human digitome, a digital representation of human health and disease, ... integration of all data sources. Dr. Michelle Longmire, Co-Founder and CEO of Medable, ...
(Date:9/22/2018)... ... September 20, 2018 , ... ... venture. The synergistic combination of Predicine’s GeneRADAR molecular insights platform with Flagship’s ... to empower clinical trials in the immuno-oncology (IO) space. , IO therapies ...
(Date:9/13/2018)... ... September 13, 2018 , ... Asymmetrex’s director, James ... would have gotten in medicine, if we didn’t have the means to measure the ... patients?” His answer, “Nowhere! And that is what’s holding up progress in stem ...
Breaking Biology Technology:
Cached News: